TAC1, tachykinin precursor 1, 6863

N. diseases: 478; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Subjective pain (assessed by visual analogue scale in pain diary and by chairside archwire activation), periodontal status (assessed by periodontal clinical parameters), cytokines in gingival crevicular fluid (interleukin 1β, prostaglandin E<sub>2</sub>, substance P) and periodontopathic bacteria (Porphyromonas gingivalis and Treponema denticola) in supragingival plaque were assessed. 31833004 2020
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE The combination of both bradykinin and substance P reporter substances with specific enzyme inhibitors will shed more light on biochemical pathways in inflammatory processes and pain. 31718985 2020
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE In the central nervous system, substance P participates in the regulation of pain, learning, memory, and sexual homeostasis. 31807924 2020
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE In chronic pain, the substance P (SP) neurokinin 1 receptor (NK<sub>1</sub>R) redistributes from the plasma membrane to acidified endosomes, where it signals to maintain pain. 31686009 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Various inhibitors of TRPV1, TRPV2, TRPM8, Piezo 2, ASICs, P2X, P2Y, B1, B2, AMPA, NMDA, mGlu, NK1 and CGRP receptors have shown high therapeutic value in experimental models of pain. 30706780 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE The expression of TRPV1, ASIC-3, TDV8 encode ionic channels in RA and modulate the pain, likewise, the transcription factors in RA, such as TNFα, TGF-β1, IL-6, IL-10, IFN-γ, IL-1b, mTOR, p21, caspase 3, EDNRB, CGRP-CALCB, CGRP-CALCA, TAC1 are also directly involved in pain perception. 31419924 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Compounds that inhibit SP's action are being investigated as potential drugs to relieve pain. 30284083 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE This double-blind, randomized, crossover study compared the local anesthetic effect of CTY-5339A versus 14% benzocaine alone by using 2 quantitative sensory threshold experimental pain paradigms on the maxillary gingiva: pin prick test pain intensity (PPT PI) and heat pain threshold (HPT). 30660443 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Membrane metallo-endopeptidase (MME), also known as neprilysin (NEP), has been of interest for its role in neurodegeneration and pain due to its ability to degrade β-amyloid and substance-P, respectively. 31339187 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Substance P is an eleven-amino acid neuropeptide (undecapeptide) with multiple effects on the gastrointestinal, cardiovascular, and urinary systems as well as complex central nervous system functions such as pain, learning, memory, and sexual homeostasis. 31147779 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Moreover, genes associated with neuropathic pain including Maob, Grin2b/NMDAR2b, TrpV3, IL-6, Cacna1b/Ca<sub>v</sub>2.2, Itgam/Cd11b, Scn9a/Na<sub>v</sub>1.7, and Tac1 were all found to respond to the celecoxib loaded nanoemulsion during pain relief as compared to those animals that received drug-free vehicle. 31652890 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE A possible mechanism for the effect of LLLT on fibromyalgia pain is via the antinociceptive signaling of substance P in muscle nociceptors, although the neuropeptide has been known as a neurotransmitter to facilitate pain signals in the spinal cord. 30908578 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE The best-known TK is the vertebrate substance P, which in mammals, together with other TKs, has been implicated in health and disease with important roles in pain, inflammation, cancer, depressive disorder, immune system, gut function, hematopoiesis, sensory processing, and hormone regulation. 31824255 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere? 30468743 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE This study tested the hypothesis that SP evoked SP-NK-I receptor positive feedback via the Renin-Angiotensin System/B-Protein Kinase A-Rapidly Accelerates Fibrosarcoma-MEK-Extracellular Signal-Regulated Kinase (RAS/PKA-RAF-MEK-ERK) pathway, which is involved in pain hypersensitivity. 31705725 2019
CUI: C0030193
Disease: Pain
Pain
0.600 AlteredExpression phenotype BEFREE Nevertheless, it may be proposed that the HCN channel activity is modulated by endogenous opioids and cyclo-oxygenase-2, whereas the activation of these channels may modulate the actions of substance P and the expression of spinal N-methyl-D-aspartate receptor subunit 2B to modulate pain. 30768426 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE However, PPT pain was not significantly different between the two bouts of exercise. 30805713 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Substance P (SP), an 11-amino-acid neuropeptide, has long been considered an effector of pain. 30935032 2019
CUI: C0030193
Disease: Pain
Pain
0.600 AlteredExpression phenotype BEFREE SQ inhibited the numbers of writhing response (<i>P</i> < 0.05), formalin-induced pain and decreased COX-2 and substance P expression in the tumor tissue compared to control mice and also enhanced the antitumor efficacy of DOX in allograft mice. 31179755 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE In this study, we investigated whether SP is involved in inflammatory orofacial pain by upregulating interleukin (IL)-1β and tumour necrosis factor (TNF)-α from SGCs, and we explored whether MAPK signalling pathways mediate the pain process. 31501412 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Substance P, calcitonin gene-related peptide, vasoactive intestinal peptide and neuropeptide Y are the major peptides involved both in the generation of pain as well as reducing pain post-joint trauma. 30039292 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE The labels of nerve fibers and pain transmission indicators were as follows: Neurofilament‑200 and substance P. Calcitonin gene‑related peptide was upregulated in the synovium of severe DDH in contrast to that in the synovium of moderate DDH. 30720141 2019
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE Significant correlations were observed between pain and drainage and TAC1, CUPRAC, and FRAP and between xerostomia and the TAC1, TAC2, CUPRAC, and FRAP. 29992150 2018
CUI: C0030193
Disease: Pain
Pain
0.600 GeneticVariation phenotype BEFREE Accordingly, the inflamed bladders expressed increased levels of mRNA for proinflammatory cytokines (IL-1β and IL-6) and pain mediator (substance P precursor). 29700406 2018
CUI: C0030193
Disease: Pain
Pain
0.600 Biomarker phenotype BEFREE To delete NK1+ neurons for the purpose of pain control, we generated a toxin–peptide conjugate using DTNB-derivatized (Cys0) substance P (SP) and a N-terminally truncated Pseudomonas exotoxin (PE35) that retains the endosome-release and ADP-ribosylation enzymatic domains but with only one free sulfhydryl side chain for conjugation. 28814145 2018